Citations

Clear

4610 citation(s) found for "Lu, Brian".

Hepatorenal Syndrome: A Review of Pathophysiology and Current Treatment Options
Erly, Brian , Carey, William, Kapoor, Baljendra , McKinney, J. Mark , Tam, Mathew, Wang, Weiping , Wang, Weiping

Mayo Clinic

Seminars in Interventional Radiology | November 10, 2015 | Volume: 32 | Issue: 04 | Pages: 445-454

10.1055/s-0035-1564794 | PMID 26622108 Get It

Adult patients with supratentorial pilocytic astrocytoma: long-term follow-up of prospective multicenter clinical trial NCCTG-867251 (Alliance)
Brown, Paul D. , Anderson, S. Keith , Carrero, Xiomara W., Galanis, E., Shah, Sunjay, Abrams, Ross A. , Curran, Walter J. , Buckner, Jan C. , Shaw, Edward G. , O'Neill, Brian P, Galanis, Eva, Shah, Sunjay A, O’Neill, Brian Patrick , Giannini, Caterina

Mayo Clinic

Neuro-Oncology Practice | November 5, 2015 | Volume: 2 | Issue: 4 | Pages: 199-204

10.1093/nop/npv031 | PMID 26640699 Get It

Abstract Background Pilocytic astrocytoma is a rare tumor in adults. This report is of a prospective clinical trial with long-term follow-up. Methods Between 1986 and 1994, 20 eligible adults with supratentorial pilocytic astrocytomas were enrolled in a prospective intergroup trial of radiotherapy (RT) after biopsy (3 patients) or observation after gross (11 patients) or subtotal (6 patients) resection. Results At the time of analysis (median follow-up, 20.8 years), 2 patients (10%) have died and 18 patients (90%) are alive. Neurologic and cognitive function were stable or improved over time for the majority of patients. No toxic effects of treatment or malignant transformations have been recorded at last follow-up. For the entire cohort the 20-year time to progression and overall survival rates are 95% and 90% respectively. The cause of death (2.2 and 16.1 years after enrollment) in both patients was unrelated to tumor although both were biopsy-only patients. One subtotally resected tumor progressed 1 month after enrollment requiring P32 injection into an enlarging cyst. Because of further progression this patient required RT 18 months later. This patient is alive without evidence of progression 18 years after RT. Conclusion The long-term follow-up results of this prospective trial confirm that adults with pilocytic astrocytomas have a favorable prognosis with regard to survival and neurologic function. Close observation is recommended for adults with pilocytic astrocytomas, reserving RT for salvage, as the majority remain stable after gross or subtotal resection and no adjuvant therapy.
ISDN2014_0276: Peripheral innervation in children with developmental delay: A risk marker for self‐injurious behavior?
Tervo, Raymond C., Symons, Frank J. , Damerow, John A., Suski, Erica, Foster, S., Panoutsopoulou, Ioanna G., Wendelschafer‐Crabb, Gwen, Burkitt, Chantel C. , McAdams, Brian , Kennedy, William R.

Mayo Clinic

International Journal of Developmental Neuroscience | November 5, 2015 | Volume: 47 | Issue: Part_A | Pages: 82-82

10.1016/j.ijdevneu.2015.04.224 Get It

The Impact of Prior Radiation Therapy on Artificial Urinary Sphincter Device Survival
Rivera, Marcelino , Linder, Brian J. , Ziegelmann, Matthew , Viers, Boyd R. , Rangel, Laureano J. , Elliott, Daniel S. , Rivera, Marcelino E, Ziegelmann, Matthew J, Linder, Brian J , Viers, Boyd R

Mayo Clinic

Journal of Urology | October 30, 2015 | Volume: 195 | Issue: 4 Part 1 | Pages: 1033-1037

10.1016/j.juro.2015.10.119 | PMID 26518111 Get It

Artificial Urinary Sphincter Mechanical Failures—Is it Better to Replace the Entire Device or Just the Malfunctioning Component?
Linder, Brian J. , Viers, Boyd R. , Ziegelmann, Matthew , Rivera, Marcelino , Rangel, Laureano J. , Elliott, Daniel S. , Ziegelmann, Matthew J, Rivera, Marcelino E, Linder, Brian J , Viers, Boyd R

Mayo Clinic

Journal of Urology | October 23, 2015 | Volume: 195 | Issue: 5 | Pages: 1523-1528

10.1016/j.juro.2015.10.084 | PMID 26493494 Get It

Personalized risk prediction for event‐free survival at 24 months in patients with diffuse large B‐cell lymphoma
Jaïs, Jean‐Philippe , Ghesquières, Hervé , Thompson, Carrie A. , Thiéblemont, Catherine , Micallef, Ivana N. , Porrata, Luis F. , Nowakowski, G. S., Casasnovas, Olivier , Bologna, Serge, Morrison, Vicki A., Macon, William R. , Copie‐Bergman, Christiane , Feldman, Andrew L. , Syrbu, Sergei , Kurtin, Paul J. , Gascoyne, Randy D. , Li, Hailun , Allmer, Cristine, Ansell, Stephen M. , Link, Brian K. , Salles, Gilles , Tilly, Hervé , Nowakowski, Gregorz S, Maurer, Matthew J. , Witzig, Thomas E. , Hong, Fangxin , Haïoun, Corinne , Ribrag, Vincent , Morschhauser, Franck , Peterson, Bruce A. , Kahl, Brad S. , Slager, Susan L. , Habermann, Thomas M. , Cerhan, James R. , Feldman, Andrew L , Link, Brian K , Salles, Gilles A , Syrbu, Sergei , Casasnovas, René-Olivier

Mayo Clinic

American Journal of Hematology | October 22, 2015 | Volume: 91 | Issue: 2 | Pages: 179-184

10.1002/ajh.24223 | PMID 26492520 Get It

We recently defined event‐free survival at 24 months (EFS24) as a clinically relevant outcome for patients with DLBCL. Patients who fail EFS24 have very poor overall survival, while those who achieve EFS24 have a subsequent overall survival equivalent to that of the age‐ and sex‐matched general population. Here, we develop and validate a clinical risk calculator (IPI24) for EFS24. Model building was performed on a discovery dataset of 1,348 patients with DLBCL and treated with anthracycline‐based immunochemotherapy. A multivariable model containing age, Ann Arbor stage, normalized serum LDH, ALC, ECOG performance status, bulky disease, and sex was identified. The model was then applied to an independent validation dataset of 1,177 DLBCL patients. The IPI24 score estimates the probability of failing to achieve the EFS24 endpoint for an individual patient. The IPI24 model showed superior discriminatory ability (c‐statistic = 0.671) in the validation dataset compared to the IPI (c‐statistic = 0.649) or the NCCN‐IPI (c‐statistic = 0.657). After recalibration of the model on the combined dataset, the median predicted probability of failing to achieve EFS24 was 36% (range, 12–88%), and the IPI24 showed an EFS24 gradient in all IPI groups. The IPI24 also identified a significant percentage of patients with high risk disease, with over 20% of patients having a 50% or higher risk of failing to achieve EFS24. The IPI24 provides an individual patient level probability of achieving the clinically relevant EFS24 endpoint. It can be used via electronic apps. Am. J. Hematol. 91:179–184, 2016. © 2015 Wiley Periodicals, Inc.
P05.15: False positive MaterniT21 PLUS with vanishing twin
Borowski, Kristi, Rose, Connie E., Keating, Elizabeth M. , Brost, Brian , White, Wendy , Davies, N.

Mayo Clinic

Ultrasound in Obstetrics & Gynecology | October 13, 2015 | Volume: 42 | Issue: s1 | Pages: 132-132

10.1002/uog.12979 Get It

Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer
Hurley, Paula J. , Sundi, Debasish , Shinder, Brian , Hughes, Robert M. , Miller, Rebecca M., Benzon, Benjamin , Faraj, Sheila F., Netto, George J. , Vergara, Ismael A. , Erho, Nicholas , Karnes, R. Jeffrey , Yan, Guifang, Ewing, Charles M., Isaacs, Sarah D., Berman, David M. , Rider, Jennifer R. , Jordahl, Kristina M. , Mucci, Lorelei A. , Huang, Jessie , An, Steven S. , Isaacs, William B. , Marchionni, Luigi , Ross, Ashley E. , Schaeffer, Edward M. , Simons, Brian W. , Davicioni, Elai , Park, Ben Ho

Mayo Clinic

Clinical Cancer Research | October 7, 2015 | Volume: 22 | Issue: 2 | Pages: 448-458

10.1158/1078-0432.ccr-15-0256 | PMID 26446945 Get It

Abstract Purpose: Prostate cancers incite tremendous morbidity upon metastatic growth. We previously identified Asporin (ASPN) as a potential mediator of metastatic progression found within the tumor microenvironment. ASPN contains an aspartic acid (D)-repeat domain and germline polymorphisms in D-repeat-length have been associated with degenerative diseases. Associations of germline ASPN D polymorphisms with risk of prostate cancer progression to metastatic disease have not been assessed. Experimental Design: Germline ASPN D-repeat-length was retrospectively analyzed in 1,600 men who underwent radical prostatectomy for clinically localized prostate cancer and in 548 noncancer controls. Multivariable Cox proportional hazards models were used to test the associations of ASPN variations with risk of subsequent oncologic outcomes, including metastasis. Orthotopic xenografts were used to establish allele- and stroma-specific roles for ASPN D variants in metastatic prostate cancer. Results: Variation at the ASPN D locus was differentially associated with poorer oncologic outcomes. ASPN D14 [HR, 1.72; 95% confidence interval (CI), 1.05–2.81, P = 0.032] and heterozygosity for ASPN D13/14 (HR, 1.86; 95% CI, 1.03–3.35, P = 0.040) were significantly associated with metastatic recurrence, while homozygosity for the ASPN D13 variant was significantly associated with a reduced risk of metastatic recurrence (HR, 0.44; 95% CI, 0.21–0.94, P = 0.035) in multivariable analyses. Orthotopic xenografts established biologic roles for ASPN D14 and ASPN D13 variants in metastatic prostate cancer progression that were consistent with patient-based data. Conclusions: We observed associations between ASPN D variants and oncologic outcomes, including metastasis. Our data suggest that ASPN expressed in the tumor microenvironment is a heritable modulator of metastatic progression. Clin Cancer Res; 22(2); 448–58. ©2015 AACR.
Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation
Spratt, Daniel E. , Doran, Michael G. , Lee, Man Xia, Shah, Neel , Wongvipat, John, Carnazza, Kathryn E., Klee, George G., Polkinghorn, William R., Tindall, Donald J., Lewis, Jason S. , Davis, Brian J. , Evans, Michael J. , Lee, Man Xia, Sawyers, Charles L. , Spratt, Daniel E

Mayo Clinic

Cancer Research | October 2, 2015 | Volume: 75 | Issue: 22 | Pages: 4688-4696

10.1158/0008-5472.can-15-0892 | PMID 26432404 Get It

Abstract Clinical trials have established the benefit of androgen deprivation therapy (ADT) combined with radiotherapy in prostate cancer. ADT sensitizes prostate cancer to radiotherapy-induced death at least in part through inhibition of DNA repair machinery, but for unknown reasons, adjuvant ADT provides further survival benefits. Here, we show that androgen receptor (AR) expression and activity are durably upregulated following radiotherapy in multiple human prostate cancer models in vitro and in vivo. Moreover, the degree of AR upregulation correlates with survival in vitro and time to tumor progression in animal models. We also provide evidence of AR pathway upregulation, measured by a rise in serum levels of AR-regulated hK2 protein, in nearly 20% of patients after radiotherapy. Furthermore, these men were three-fold more likely to experience subsequent biochemical failure. Collectively, these data demonstrate that radiotherapy can upregulate AR signaling after therapy to an extent that negatively affects disease progression and/or survival. Cancer Res; 75(22); 4688–96. ©2015 AACR.
Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures
Flanagan, Eoin P. , McKeon, Andrew , Watson, Robert E. , Klein, Christopher J. , Lowe, Val J. , Ahlskog, J. Eric , Shin, Cheolsu, Laughlin, Ruple S. , Pittock, Sean J. , Kotsenas, Amy L. , Boes, Christopher J. , Crum, Brian A. , Pittock, S J , Britton, Jeffrey W. , Boeve, Bradley F. , Flanagan, E P , Klein, Christopher J , McKeon, Andrew

Mayo Clinic

Neurology Neuroimmunology & Neuroinflammation | October 2, 2015 | Volume: 2 | Issue: 6 | Pages: No page available

10.1212/nxi.0000000000000161 | PMID 26468474 Get It